GlobeNewswire: NexImmune, Inc. Contains the last 10 of 75 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:30:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/06/2824768/0/en/NexImmune-Announces-Closing-of-3-67-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=31508NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules2024-02-06T21:42:41Z<![CDATA[GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also issued unregistered warrants to purchase up to an aggregate of 304,731 shares of its common stock at an exercise price of $12.05 per share. The warrants are exercisable immediately and have a term of two years from the date of issuance.]]>https://www.globenewswire.com/news-release/2024/02/02/2823027/0/en/NexImmune-Announces-3-67-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=31508NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules2024-02-02T19:00:00Z<![CDATA[GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 304,731 shares of its common stock. The unregistered warrants to be issued in this private placement will have an exercise price $12.05 per share, will become exercisable immediately upon issuance and have a term of two years from the date of issuance. The closing of the offering is expected to occur on or about February 6, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2023/10/24/2765592/0/en/NexImmune-Yale-and-JDRF-Extend-Research-Partnership-for-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=31508NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes2023-10-24T12:00:00Z<![CDATA[GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).]]>https://www.globenewswire.com/news-release/2023/10/19/2763112/0/en/NexImmune-Announces-Presentations-at-The-Society-for-Immunotherapy-of-Cancer-s-38th-Annual-Meeting.html?f=22&fvtc=4&fvtv=31508NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting2023-10-19T12:00:00Z<![CDATA[GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023.]]>https://www.globenewswire.com/news-release/2023/10/18/2762610/0/en/NexImmune-Announces-1-for-25-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=31508NexImmune Announces 1-for-25 Reverse Stock Split2023-10-18T15:30:00Z<![CDATA[GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company’s common stock at a special meeting of the Company held on October 17, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Wednesday, October 18, 2023. The Company’s common stock will open for trading under a new CUSIP number 65344D 208 on The Nasdaq Capital Market on October 19, 2023, on a split-adjusted basis under the current ticker symbol "NEXI." The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.]]>https://www.globenewswire.com/news-release/2023/08/31/2735724/0/en/NexImmune-Announces-Workforce-Reduction-to-Enable-Continued-AIMTM-Nanoparticle-Platform-Development-Strategy.html?f=22&fvtc=4&fvtv=31508NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy2023-08-31T20:45:00Z<![CDATA[GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, designed to reduce costs and extend the Company’s cash. The realignment will reduce the Company’s workforce from 47 to 22 full-time employees as of September 5, 2023.]]>https://www.globenewswire.com/news-release/2023/08/10/2723104/0/en/NexImmune-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html?f=22&fvtc=4&fvtv=31508NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates2023-08-10T20:01:00Z<![CDATA[GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the second quarter of 2023.]]>https://www.globenewswire.com/news-release/2023/06/05/2681928/0/en/NexImmune-Presents-Initial-Positive-Data-from-the-NEXI-001-Phase-1-Trial-for-Relapsed-Refractory-Post-Allo-HSCT-AML-at-the-American-Society-of-Clinical-Oncology-2023-Annual-Meeting.html?f=22&fvtc=4&fvtv=31508NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting2023-06-05T12:01:00Z<![CDATA[- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy]]>https://www.globenewswire.com/news-release/2023/05/22/2673784/0/en/NexImmune-Announces-Poster-Presentation-at-the-2023-FOCIS-Annual-Meeting.html?f=22&fvtc=4&fvtv=31508NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting2023-05-22T20:01:00Z<![CDATA[AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease]]>https://www.globenewswire.com/news-release/2023/05/15/2669273/0/en/NexImmune-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html?f=22&fvtc=4&fvtv=31508NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates2023-05-15T20:01:00Z<![CDATA[GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the first quarter 2023.]]>